GeoVax Labs Files 8-K Report
Ticker: GOVX · Form: 8-K · Filed: Oct 1, 2024 · CIK: 832489
Sentiment: neutral
Topics: 8-k, filing, other-event
Related Tickers: GOVX
TL;DR
GeoVax Labs (GOVX) filed an 8-K on Oct 1st - details on a new event.
AI Summary
On October 1, 2024, GeoVax Labs, Inc. filed an 8-K report detailing an "Other Event." The filing does not specify the exact nature of this event but is a standard current report filed with the SEC.
Why It Matters
This filing indicates a material event has occurred for GeoVax Labs, Inc. that requires public disclosure to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for an 'Other Event' and does not contain specific financial or operational details that would immediately indicate high risk.
Key Players & Entities
- GeoVax Labs, Inc. (company) — Registrant
- October 1, 2024 (date) — Date of report
- 001-39563 (other) — Commission File Number
- 87-0455038 (other) — IRS Employee Identification No.
FAQ
What specific event is GeoVax Labs, Inc. reporting in this 8-K filing?
The filing is categorized under 'Other Events' and does not provide specific details about the event itself within the provided text.
When was this 8-K report filed with the SEC?
The report was filed on October 1, 2024.
What is the exact name of the registrant?
The exact name of the registrant is GeoVax Labs, Inc.
In which state is GeoVax Labs, Inc. incorporated?
GeoVax Labs, Inc. is incorporated in Delaware.
What is the Commission File Number for GeoVax Labs, Inc.?
The Commission File Number for GeoVax Labs, Inc. is 001-39563.
Filing Stats: 529 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-10-01 17:17:28
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share GOVX The Nasdaq Capital M
Filing Documents
- govx20241001_8k.htm (8-K) — 26KB
- 0001437749-24-030377.txt ( ) — 170KB
- govx-20241001.xsd (EX-101.SCH) — 4KB
- govx-20241001_def.xml (EX-101.DEF) — 13KB
- govx-20241001_lab.xml (EX-101.LAB) — 17KB
- govx-20241001_pre.xml (EX-101.PRE) — 13KB
- govx20241001_8k_htm.xml (XML) — 5KB
01
Item 8.01 Other Events. The Company re-convened a Special Meeting of Stockholders (the "Special Meeting") on October 1, 2024 (originally convened on September 17, 2024) and adjourned the Special Meeting without any business being conducted due to lack of the required quorum. The Company has determined to keep the polls open and reconvene the Special Meeting on October 16, 2024 at 8:30 a.m. Eastern Time to provide its stockholders additional time to vote on the proposals described in the proxy statement filed with the Securities and Exchange Commission on August 1, 2024. No changes have been made to the proposals to be voted on by stockholders at the Special Meeting. At the time the Special Meeting was adjourned, proxies had been submitted by stockholders representing approximately 27% of the shares of the Company's common stock outstanding and entitled to vote. Proxies previously submitted in respect of the Special Meeting will be voted at the reconvened Special Meeting unless properly revoked, and stockholders who have previously submitted a proxy or otherwise voted need not take any action.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GeoVax Labs, Inc. October 1, 2024 By: /s/ Mark W. Reynolds Name: Mark W. Reynolds Title: Chief Financial Officer